- Home
- MGRX vs SBFM Comparison
MGRX vs SBFM Comparison
Compare MGRX & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- SBFM
- Stock Information
- Founded
- MGRX 2021
- SBFM 2006
- Country
- MGRX United States
- SBFM United States
- Employees
- MGRX N/A
- SBFM N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- SBFM Health Care
- Exchange
- MGRX Nasdaq
- SBFM Nasdaq
- Market Cap
- MGRX 7.0M
- SBFM 3.7M
- IPO Year
- MGRX 2023
- SBFM N/A
- Fundamental
- Price
- MGRX $2.50
- SBFM $3.14
- Analyst Decision
- MGRX
- SBFM
- Analyst Count
- MGRX 0
- SBFM 0
- Target Price
- MGRX N/A
- SBFM N/A
- AVG Volume (30 Days)
- MGRX 1.0M
- SBFM 90.8K
- Earning Date
- MGRX 10-29-2024
- SBFM 11-11-2024
- Dividend Yield
- MGRX N/A
- SBFM N/A
- EPS Growth
- MGRX N/A
- SBFM N/A
- EPS
- MGRX N/A
- SBFM N/A
- Revenue
- MGRX $866,792.00
- SBFM $30,481,982.00
- Revenue This Year
- MGRX N/A
- SBFM $86.70
- Revenue Next Year
- MGRX N/A
- SBFM $126.76
- P/E Ratio
- MGRX N/A
- SBFM N/A
- Revenue Growth
- MGRX 245.48
- SBFM 109.82
- 52 Week Low
- MGRX $2.15
- SBFM $2.42
- 52 Week High
- MGRX $16.80
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- MGRX 32.69
- SBFM 52.62
- Support Level
- MGRX $2.20
- SBFM $2.85
- Resistance Level
- MGRX $2.83
- SBFM $3.05
- Average True Range (ATR)
- MGRX 0.41
- SBFM 0.14
- MACD
- MGRX -0.06
- SBFM 0.03
- Stochastic Oscillator
- MGRX 8.44
- SBFM 85.29
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.